Data from EMC - Curated by Toby Galbraith - Last updated 16 March 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component
formulation.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more

Visit Type 2 Diabetes

More information

Category Value
Agency product number EMEA/H/C/001159
Orphan designation No
Date First Approved 04-11-2009
Type POM
Marketing authorisation holder Novartis Europharm Ltd.

Related Content